ProCE Banner Activity

Biomarker Summary: ROS1

PDF
Get up to date on the clinical role of ROS1 rearrangements in nonsquamous NSCLC, including FDA-approved targeted therapies and diagnostic methods, with this downloadable PDF resource.

Released: May 31, 2019

Expiration: May 29, 2020

No longer available for credit.

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Axel Grothey

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Michael J. Pishvaian

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

David R. Spigel

David R. Spigel, MD

Chief Scientific Officer
Director,
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Array BioPharma

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Foundation Medicine

Genentech TEXT Only

Loxo Oncology

Merck Oncology

Puma Biotechnology, Inc.

Program Director Disclosure

Program Director

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

David R. Spigel, MD

Chief Scientific Officer
Director,
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee